Bambusa Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in the Boston Seaport, founded in 2024 by Shanshan Xu and Helmut Jeggle to develop next-generation bispecific antibodies for immunological and inflammatory (I&I) diseases. Its antibody-engineering platform combines half-life extension with high-concentration subcutaneous delivery, and its pipeline spans dermatology, respiratory, gastroenterology and rheumatology — led by BBT-001 (IL-31 x IL-4Ralpha, in a Phase 1b/2a atopic dermatitis trial) and BBT-002 for COPD. The company raised a Series Seed in 2024, an approximately $90M Series A led by RA Capital Management in February 2025, and an oversubscribed Series A-2 in November 2025. It is a therapeutics developer, not a software vendor, and publishes no public API, SDK or developer program.
Bambusa Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Immunology.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: bambusa-therapeutics
name: Bambusa Therapeutics
description: Bambusa Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in the Boston Seaport, founded
in 2024 by Shanshan Xu and Helmut Jeggle to develop next-generation bispecific antibodies for immunological and inflammatory
(I&I) diseases. Its antibody-engineering platform combines half-life extension with high-concentration subcutaneous delivery,
and its pipeline spans dermatology, respiratory, gastroenterology and rheumatology — led by BBT-001 (IL-31 x IL-4Ralpha,
in a Phase 1b/2a atopic dermatitis trial) and BBT-002 for COPD. The company raised a Series Seed in 2024, an approximately
$90M Series A led by RA Capital Management in February 2025, and an oversubscribed Series A-2 in November 2025. It is a
therapeutics developer, not a software vendor, and publishes no public API, SDK or developer program.
url: https://raw.githubusercontent.com/api-evangelist/bambusa-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Immunology
- Clinical Trials
- Drug Development
- Antibodies
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/bambusa-therapeutics-domain-security.yml
- type: Website
url: https://bambusatx.com/
- type: About
url: https://bambusatx.com/about/
- type: SecondaryMarket
url: https://forgeglobal.com/bambusa-therapeutics_stock/
x-enrichment:
date: '2026-08-06'
status: minimal
artifacts_added: 1
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Bambusa is a 2024-founded clinical-stage antibody developer whose only web property, bambusatx.com, is a marketing
site sitting entirely behind a SiteGround captcha (every path, including /, answers 202 with an sgcaptcha redirect), while
DNS resolves no api./docs./developers./portal. host and no company GitHub organization exists — the product is a bispecific-antibody
pipeline, not software, so there is no API to publish.
evidence:
- url: https://bambusatx.com/openapi.json
status: 202
- url: https://bambusatx.com/.well-known/agent-card.json
status: 202
- url: https://bambusatx.com/.well-known/security.txt
status: 202
- url: https://bambusatx.com/
status: 202
checked: '2026-08-06'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →